It gives us great pleasure to announce the arrival of Dr. Andrew Feilden at Hall Analytical as the strategic director for extractables and leachables for Europe. In his role, Andrew will work across the organisation to define market opportunities, position Hall Analytical as a thought leader within the extractables and leachables space, and create value for Hall Analytical’s customers by developing new allegiances.

Andrew is an experienced analytical chemist with over 20 years’ experience in the field of trace organic analysis, where he predominantly focussed on extractables and leachables.

He has become a leading authority on extractables and leachables, presenting in over 15 countries including India, Japan, China, and the USA.  Andrew was also co-chair of the ELSIE group and was a scientific advisor to IPAC-RS. His previous work experience includes 2 key roles;

  • Operations director at a contract research organisation – where he grew the size of the group and passed audits by the FDA, MHRA, and UKAS
  • Senior scientist at a large pharma corp.  – where he worked on numerous dosage forms and wrote regulatory documents including NDAs, IMPDs, and INDs.

He has a degree and D Phil from the University of York, is a Fellow of the Royal Society of Chemistry and is the inventor of two patents. Using his vast experience and knowledge, Andrew is an invaluable addition to the Hall Analytical team, benefitting our customers equally.